Kevin Malobisky

Outlook Microsoft Office 365 Remote AI

allergy food & pediatric allergy specific immunotherapy biotechnology: biological products (no diagnostic substances) health care biotechnology research food allergies peanut allergy viaskin technology epicutaneous immunotherapy clinical trials immunological diseases viaskin peanut cows milk allergy eoe treatment immune system re-education investigational therapies patch-based treatment biopharmaceutical company pediatric clinical trials non-ige-mediated allergies pharmaceutical research safety & efficacy treatment options patient care allergic reactions anaphylaxis prevention innovative healthcare diagnostic tools atopy patch test safety data long-term studies collaboration with hospitals allergy research clinical development programs phase 3 trials allergy treatment advancements children with allergies gluten-free solutions autoimmune disease research scientific publications consumer health solutions international healthcare investor relations biotechnology innovations patient-centered approach regulatory approval immune therapy therapeutic advancements global health initiatives medical need clinical effectiveness healthcare investments life science partnerships biopharmaceutical immunotherapy non-invasive treatment cow's milk allergy pediatric care allergen desensitization innovative therapies patient-centric care healthcare solutions allergy management health-conscious parents urban healthcare access treatment pipeline clinical-stage company fda fast track designation allergy patch therapeutic innovation quality of life improvement healthcare collaboration market research digital engagement health advocacy health wellness & fitness hospital & health care